|Bid||2.67 x 1100|
|Ask||5.49 x 800|
|Day's Range||5.38 - 5.49|
|52 Week Range||4.35 - 22.18|
|Beta (5Y Monthly)||0.88|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for MOR
My name is Julia Neugebauer, senior director investor relations at MorphoSys, and it is my pleasure to welcome you to our first quarter 2022 financial results conference call. Joining me on the call today are Jean-Paul Kress, chief executive officer; Sung Lee, chief financial officer; Malte Peters, chief research and development officer; and Joe Horvat, U.S. general manager.
The mean of analysts' price targets for MorphoSys AG Unsponsored ADR (MOR) points to a 213.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The Swiss agency for therapeutic products has granted temporary approval for MorphoSys AG (NASDAQ: MOR) and Incyte Corp's (NASDAQ: INCY) Minjuvi (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The approval comes for Minjuvi combined with lenalidomide, followed by Minjuvi monotherapy for adult patients, after at least one prior line of systemic therapy, who are not eligible for autologous stem cell transplant (ASCT). The approval is based on the results from the L-